| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H26N6O |
| Molecular Weight | 450.5349 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)C2=CC3=CC=C(CCNC4=C5C=C(C=CC5=NC=N4)C#N)C=C3C=C2
InChI
InChIKey=VNADJTWHOAMTLY-UHFFFAOYSA-N
InChI=1S/C27H26N6O/c1-32-10-12-33(13-11-32)27(34)23-6-5-21-14-19(2-4-22(21)16-23)8-9-29-26-24-15-20(17-28)3-7-25(24)30-18-31-26/h2-7,14-16,18H,8-13H2,1H3,(H,29,30,31)
| Molecular Formula | C27H26N6O |
| Molecular Weight | 450.5349 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Senexin B is a selective CDK8/CDK19 inhibitor developed by Senex Biotechnology Inc. Senexin B is an ATP pocket binder, with very high target selectivity as indicated by kinome profiling. CDK8/19 inhibition produces chemopotentiating, chemopreventive and anti-metastatic effects in different types of cancer.
Originator
Approval Year
Patents
Sample Use Guides
CB-17 SCID mice (8 weeks old) received 5 daily i.p. injections of SNX2-1-165 (40 mg/kg) or carrier only, 10 mice per group. Mice were then injected s.c. with 1 x 106 cells of human A549 lung cancer cell line; the tumor cells were injected in the afternoon of the same day when the last dose of treatment was administered in the morning. Starting from day 7 after tumor injection, mice were monitored for tumor formation twice a week, with 3-4 day intervals, until day 24 after tumor injection; tumor volumes were calculated via caliper measurements.
Route of Administration:
Intraperitoneal
MDA-MB-468 and MDA-MB-157 cells were plated in 96-well plates, at 1,500 cells/well, and exposed to carrier or increasing concentrations of SNX2-1-165 (SENEXIN B) for five days; cell survival was measured by the MTT assays. MDA-MB-468 and MDA-MB-157 displayed dose-dependent growth inhibition by SNX2-1-165.
